ATAI Life Sciences N.V.

ATAI - CIK 0001840904

Market cap$1.40 B

Rank#2384

SEC filings320

ATAI Life Sciences N.V. trades as ATAI and has a market capitalization of $1.40 B, making it the #2384 largest US-listed company by market value. In its fiscal 2024 annual report the company posted revenue of $308.00K, down 1.9% from the prior year and net income of -$149.27M. This page tracks ATAI Life Sciences N.V. through 320 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$308.00KFY 2024

Net income (latest FY)-$149.27MFY 2024

Operating cash flow (latest FY)-$82.44MFY 2024

Total assets (latest FY)$159.39MFY 2024

Net margin-48464.0%latest FY

Financial performance

Net profit margin compressed from -823.6% to -48464.0% over the same period - every figure below comes from the company's audited annual filings.

ATAI annual revenueView details

ATAI annual net incomeView details

Key statistics

Market cap: $1.40 B
Share price (derived)market cap / shares outstanding: $3.84
EPS (diluted)FY 2024: $-0.93
Shares outstandingas of 2025-11-10: 0.36B
Total equityas of 2025-09-30: $159.75M
Return on equity: -93.4%
Long-term debtas of 2025-03-31: $9.30M
Cash & equivalentsas of 2025-09-30: $30.40M

Latest filings

Filing	Type	Filed
Insider sale notice	144	2026-03-20
Insider sale notice	144	2026-02-26
15-12G	-	2025-12-31
POSASR	-	2025-12-31
S-8 POS	-	2025-12-31
Major company event	8-K	2025-12-05
424B7	-	2025-12-05
Insider trade	4	2025-11-26

Browse the full filing history (320 filings)

Recent press releases

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations2026-05-28
AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations | AtaiBeckley Inc.
AtaiBeckley to Participate in Upcoming Investor Conferences in June 20262026-05-27
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 | AtaiBeckley Inc.
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update2026-05-12
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update | AtaiBeckley Inc.
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research2026-04-27
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research | AtaiBeckley Inc.
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder2026-04-22
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder | AtaiBeckley Inc.

Similar companies

The largest companies sharing ATAI Life Sciences N.V.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T ATAI vs LLY

JNJJohnson & Johnson$573.98 B ATAI vs JNJ

ABBVAbbVie Inc.$399.47 B ATAI vs ABBV

MRKMerck & Co., Inc.$293.16 B ATAI vs MRK

AZNAstraZeneca PLC$286.27 B ATAI vs AZN

Frequently asked questions

What is ATAI Life Sciences N.V.'s market cap?

ATAI Life Sciences N.V. (ATAI) has a market capitalization of $1.40 B as of 2026-06-10, ranking #2384 among US-listed companies.

How much revenue does ATAI Life Sciences N.V. make?

ATAI Life Sciences N.V. reported revenue of $308.00K for fiscal year 2024, a decrease of 1.9% year over year.

Is ATAI Life Sciences N.V. profitable?

In its latest fiscal year ATAI Life Sciences N.V. reported a net loss of $149.27M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.